Affiliations: Hemorheology and Haemostasis Unit, Service of Clinical Pathology, La Fe University Hospital, Valencia, Spain | Internal Medicine Service, La Fe University Hospital, Valencia, Spain | Rheumatology Service, General Hospital, Valencia, Spain | Dermatology Service, La Fe University Hospital, Valencia, Spain | Epidemiology Service, Dr. Peset University Hospital, Valencia, Spain
Note: [] Corresponding author: Amparo Vayá, MD, PhD, Hemorheology and Hemostasis Unit, Service of Clinical Pathology, La Fe University Hospital, Avda. de Campanar, 21, 46009 Valencia, Spain. Tel./Fax: +34 963862714; E-mail: vaya_amp@gva.es
Abstract: Psoriasis is a systemic inflammatory disorder with increased cardiovascular risk which has been partly attributed to the increased prevalence of the metabolic syndrome (MS). However, the contribution of rheological alterations to cardiovascular risk has been scarcely investigated. In 91 psoriasis patients and in 101 healthy volunteers, we determined the rheological profile (fibrinogen, blood viscosity and erythrocyte aggregation), along with lipidic and inflammatory parameters. Patients showed statistically higher BMI, waist, triglycerides, insulin, c-reactive protein (CRP), neutrophils, lower HDL-cholesterol and a higher MS prevalence (p < 0.05). When subjects with MS were excluded from the study, patients with psoriasis still showed a worse inflammatory, lipidic and rheological profile in the above-mentioned variables compared with controls without MS (p < 0.05). The logistic regression analysis revealed that abdominal obesity and fibrinogen >384 mg/dL were independent predictors of psoriasis (OR 3.75 95% CI 1.77–7.94, p < 0.001; OR 2.95 95% CI 1.14–7.64, p = 0.025), respectively. Patients on biologics, showed less inflammation and a better rheological profile than those not on biological treatment. In conclusion, patients with psoriasis show an altered rheological profile, which may contribute to increased cardiovascular risk. Although the presence of MS worsens this profile, psoriasis per se shows rheological alterations due to both inflammation and altered metabolic parameters. Anti TNF-α treatment markedly improves the rheological profile by mostly decreasing inflammation.
